Study Evaluating Local Susceptibility Patterns Associated With Tigecycline in Comparison to Other Antibiotics
Various bacterial organisms will be tested in order to compile information regarding the effectiveness of tigecycline against certain bacteria seen in local communities.
|Study Design:||Time Perspective: Prospective|
|Official Title:||Evaluation of the Antimicrobial Activity In Vitro of Tigecycline in Comparison to Other Broad Spectrum Antibiotics in Isolates Collected From Patients|
|Study Start Date:||December 2005|
|Study Completion Date:||September 2006|
A listing of all isolates meeting the inclusion criteria will be maintained.
This is a prospective, microbiologic in vitro evaluation which will study the susceptibility of tigecycline in disk diffusion on clinical bacterial isolates collected from inpatients and outpatients. Fourteen hospital centers participated in the program. In vitro efficacy of tigecycline will be determined through the in vitro disk diffusion activity, using FDA breakpoints.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01311349
|Study Director:||Medical Monitor||Wyeth is now a wholly owned subsidiary of Pfizer|